Last reviewed · How we verify
IgM rich Immunoglobin
IgM rich Immunoglobin is a Immunoglobulin replacement therapy Small molecule drug developed by Sir Takhtasinhji General Hospital. It is currently FDA-approved for Immunoglobulin M deficiency, Sepsis and severe infections in immunocompromised patients, Post-operative infection prophylaxis. Also known as: Pentaglobin®.
IgM-rich immunoglobulin provides passive immune support by supplying IgM antibodies to enhance complement activation and opsonization of pathogens.
IgM-rich immunoglobulin provides passive immune support by supplying IgM antibodies to enhance complement activation and opsonization of pathogens. Used for Immunoglobulin M deficiency, Sepsis and severe infections in immunocompromised patients, Post-operative infection prophylaxis.
At a glance
| Generic name | IgM rich Immunoglobin |
|---|---|
| Also known as | Pentaglobin® |
| Sponsor | Sir Takhtasinhji General Hospital |
| Drug class | Immunoglobulin replacement therapy |
| Target | IgM antibodies; complement system (C1q) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
IgM is the first antibody produced during primary immune responses and is highly effective at activating the classical complement pathway. IgM-rich immunoglobulin preparations deliver exogenous IgM to boost innate immune defenses, particularly useful in immunocompromised patients or those with severe infections. This enhances pathogen neutralization and clearance through complement-mediated and antibody-dependent cellular mechanisms.
Approved indications
- Immunoglobulin M deficiency
- Sepsis and severe infections in immunocompromised patients
- Post-operative infection prophylaxis
Common side effects
- Infusion reactions (fever, chills, flushing)
- Headache
- Myalgia
- Thrombotic events
- Renal dysfunction
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IgM rich Immunoglobin CI brief — competitive landscape report
- IgM rich Immunoglobin updates RSS · CI watch RSS
- Sir Takhtasinhji General Hospital portfolio CI
Frequently asked questions about IgM rich Immunoglobin
What is IgM rich Immunoglobin?
How does IgM rich Immunoglobin work?
What is IgM rich Immunoglobin used for?
Who makes IgM rich Immunoglobin?
Is IgM rich Immunoglobin also known as anything else?
What drug class is IgM rich Immunoglobin in?
What development phase is IgM rich Immunoglobin in?
What are the side effects of IgM rich Immunoglobin?
What does IgM rich Immunoglobin target?
Related
- Drug class: All Immunoglobulin replacement therapy drugs
- Target: All drugs targeting IgM antibodies; complement system (C1q)
- Manufacturer: Sir Takhtasinhji General Hospital — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Immunoglobulin M deficiency
- Indication: Drugs for Sepsis and severe infections in immunocompromised patients
- Indication: Drugs for Post-operative infection prophylaxis
- Also known as: Pentaglobin®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing